FitzroyWDawkinsMD

Clinical Trials

• Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) Start of enrollment: 2014 Mar 01

  Terminated

  Phase 3

• A Study of Ruxolitinib in Pancreatic Cancer Patients Start of enrollment: 2014 Jun 01

  Terminated

  Phase 3

• A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2016 Dec 29

  Completed

  Phase 1, Phase 2

• An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib Start of enrollment: 2016 Nov 30

  Active, not recruiting

  Phase 2

• A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) Start of enrollment: 2017 Mar 02

  Completed

  Phase 2

• Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) Start of enrollment: 2017 Feb 15

  Completed

  Phase 1

• A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma Start of enrollment: 2018 Mar 14

  Active, not recruiting

  Phase 2

• A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease Start of enrollment: 2017 Apr 20

  Terminated

  Phase 1

• A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) Start of enrollment: 2017 Dec 18

  Active, not recruiting

  Phase 2

• A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) Start of enrollment: 2018 Aug 02

  Completed

  Phase 1

• Join now to see all